Take advantage of alternative impact metrics that better reflect the multidimensional nature of today’s research dissemination and consumption.
Determining the most effective medical or commercial strategy requires measuring what’s happening in the market via a strong insights management process. Powering your insights process with different data sources (such as social media and other online conversations, medical information, congresses, advisory boards, and field observations) is critical for a full 360-degree view of the market.
In this discussion, you’ll learn:
Digital Science held a roundtable discussion with Medical Affairs leaders in Madrid in May 2024 on the topic of scientific communications strategies assessment and their success measurements for multiple stakeholders.
The MAPS Puerto Rico Roundtable hosted by Real Chemistry in March 2024 discussed the integration of digital platforms, AI, and personalized content to enhance engagement with healthcare providers (HCPs). The panel emphasized the shift towards real-time, tailored information delivery and the importance of leveraging insights from both traditional and digital sources to support effective engagement strategies while ensuring compliance.
Share of Voice used to be a numbers game to increase sales and market share. But with the advent of the digital age, Share of Voice has come to mean more than just numbers.
Drawing on insights from a roundtable of industry leaders convened by Klick at the recent MAPS conference, let’s look at how viewing the KOL holistically can lead to new avenues of engagement and more multifaceted relationships.
In this podcast, we explore the origins of negative opinions of the pharmaceutical industry, and whether a for-profit model can support both innovation and the society’s best interests.
In every successful organization there are fundamental business processes that create value and deliver a desired output. In life science companies, one of these processes is called commercialization. Commercialization of a health care product begins from the moment of concept creation. At that point, the innovator is thinking about how to treat a disease, make a patient’s life better, or meet an unmet medical need. Over time, value is built into the asset as it moves through the product development/commercialization pathway. Medical Affairs has a key role in this product development/commercialization pathway. Often referred to as a bridge between product development and commercial, Medical Affairs contributions are essential to deliver a successful commercialization process. Understanding the commercialization process and the role Medical Affairs plays in the overall organization will assist Medical Affairs professionals to make better decisions and optimize their ability to influence the future direction of their company.
This webinar seeks to help Medical Affairs professionals better understand the business of life science companies, how their efforts impact the overall capability to commercialize a product, and contemporary ways to bridge the commercialization interface between their department and Marketing & Sales. Topics included are a discussion on organizational operations and throughput, the importance of understanding the organization/enterprise main functions and how Medical Affairs aligns with functions, and optimizing interface between commercial and Medical Affairs. Our discussants will take a Medical Affairs-centric approach to discussing business operations management issues which should be useful for all Medical Affairs functions but particularly operations, therapeutic area leadership, and aspiring Medical Affairs managers.
Upon completion of the webinar, participants should be able to:
At the end of this presentation, the participant should be able to:
Health technology and value assessment can be conducted using a variety of methods. Dr. Malone will provide an overview of those methods and an introduction on how to interpret the results from cost-effectiveness studies. This webinar will also discuss issues with defining value for health technologies, especially pharmaceuticals.